Table 3 Comparison of serum galactomannan indices between the survival and fatality groups during antifungal therapy
|  | Time | Initial (n = 30/15) | 1 week (n = 28/13) | 2 weeks (n = 25/12) | 3 weeks (n = 20/9) | 4 weeks (n = 15/9) | 6 weeks (n = 15/7) | 8 weeks (n = 14/3) | 10 weeks (n = 11/2) | 12 weeks (n = 17/0) |
|---|---|---|---|---|---|---|---|---|---|---|
GMI, median (range) | Survival group (n = 30) | 0.46 (0.15–6.19) | 0.39 (0.09–1.93) | 0.38 (0.11–2.58) | 0.33 (0.11–1.45) | 0.27 (0.18–1.81) | 0.21 (0.07–0.74) | 0.27 (0.08–2.43) | 0.17 (0.09–2.74) | 0.24 (0.09–6.98) |
Fatality group (n = 15) | 1.21 (0.08–6.70) | 1.64 (0.27–6.20) | 2.76 (0.13–6.00) | 1.34 (0.09–5.64) | 0.46 (0.24–6.21) | 1.04 (0.15–7.23) | 0.91 (0.37–5.48) | 0.37 (0.18–0.56) | NA | |
p-value | 0.015 | 0.001 | 0.004 | 0.164 | 0.060 | 0.009 | 0.032 | 0.553 | NA | |
GMI positivity | Survival group (n = 30) | 13 (43.3) | 12 (42.9) | 10 (40.0) | 7 (35.0) | 5 (33.3) | 1 (6.7) | 2 (14.3) | 3 (27.3) | 2 (11.8) |
Fatality group (n = 15) | 11 (73.3) | 10 (76.9) | 10 (83.3) | 5 (55.6) | 4 (44.4) | 4 (57.1) | 2 (66.7) | 1 (50.0) | NA | |
p-value | 0.057 | 0.042 | 0.013 | 0.422 | 0.678 | 0.021 | 0.121 | 1.000 | NA |